AltheRx Pharmaceuticals
Privately held, clinical development company focused on advancing best-in-class compounds
About AltheRx Pharmaceuticals
AltheRx Pharmaceuticals was a privately held clinical development company established in 2010. The firm's business model centered on acquiring and advancing promising drug candidates through clinical development and subsequently forming partnerships with larger biopharmaceutical companies for commercialization.
The company's formation was driven by a strategy to in-license novel products that aligned with the team's expertise. This was exemplified by its first significant milestone in March 2011, when it acquired all assets related to Solabegron from the pharmaceutical giant GlaxoSmithKline. The executive team included Shawn O'Brien as Chief Executive Officer and Eliot Ohlstein as Chief Scientific Officer. Ohlstein previously served as a Senior Vice President at GlaxoSmithKline, bringing direct experience with the newly acquired asset.
AltheRx's primary focus was the development of Solabegron, a selective beta-3 adrenoceptor agonist. This compound was positioned as a treatment for both Overactive Bladder (OAB) and Irritable Bowel Syndrome (IBS). The mechanism of Solabegron involves relaxing the bladder's smooth muscles by stimulating beta-3 receptors. Prior to the acquisition, Phase II clinical trials had already demonstrated positive results, showing a reduction in symptoms for both OAB and IBS with a favorable tolerability profile comparable to a placebo.
In June 2015, NeXeption, a biopharmaceutical management company, formed a new entity called Velicept Therapeutics with the intention of merging with AltheRx. This strategic merger was designed to advance the development of Solabegron, particularly for the OAB market. The merger was finalized in September 2015, which led to AltheRx being effectively renamed and absorbed into Velicept Therapeutics.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | May 2013 | $15M | $60M | Undisclosed | — |
Growth signals
Latest recorded traffic for AltheRx Pharmaceuticals is 0 monthly website visits. AltheRx Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AltheRx Pharmaceuticals in the Washington DC ecosystem
The AltheRx Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about AltheRx Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AltheRx Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










